BACKGROUND: Patients' needs and perspectives are important determinants of treatment success in rheumatoid arthritis (RA). Assessing patients' perspectives can help identify unmet needs and enhance the understanding of treatment benefits. OBJECTIVE: The SENSE study assessed the impact of inadequate response to disease-modifying antirheumatic drugs (DMARDs) on treatment satisfaction, disease outcomes, and patient perspectives related to RA disease management. METHODS: SENSE was a noninterventional, cross-sectional study conducted in 18 countries across Europe, Asia, and South America. Adult patients with poorly controlled RA of moderate/high disease activity were eligible. Patient satisfaction was assessed by the Treatment Satisfaction Questionnaire for Medication (TSQM v1.4). Treatment adherence, healthcare resource utilization (HRU), quality of life (QoL), work ability, digital health literacy (DHL), patient preference information, and treatment strategy were also assessed. RESULTS: A total of 1624 patients were included in the study: most were female (84.2%) and middle-aged, and mean disease duration was 10.5 years. Mean TSQM global satisfaction subscore was 60.9, with only 13.5% of patients reporting good treatment satisfaction (TSQM global ≥80). The strongest predictor of good treatment satisfaction was treatment with advanced therapies. Most patients (87.4%) reported good treatment adherence. In general, patients had impaired QoL and work ability, high HRU, and 67.4% had poor DHL. Leading treatment expectations were "general improvement of arthritis" and "less joint pain". Most patients preferred oral RA medications (60.7%) and rapid (≤1 week) onset of action (71.1%). "Increased risk for malignancies" and "increased risk for cardiovascular disease" were the least acceptable side effects. Despite suboptimal control, advanced therapies were only used in a minority of patients, and DMARD switches were planned for only half of the patients. CONCLUSION: Suboptimal disease control negatively impacts treatment satisfaction, work ability, QoL, and HRU. Data collected on patient perspectives may inform shared decision-making and optimize treat-to-target strategies for improving patient outcomes in RA.

5 A Nasonova Research Institute of Rheumatology Moscow Russian Federation

AbbVie Inc North Chicago IL USA

Botnar Research Centre Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences University of Oxford Oxford UK

CEIM Investigaciones Medicas Buenos Aires Argentina

Department of Immunology and Rheumatology Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan

Department of Internal Medicine Division of Clinical Immunology Allergology and Rheumatology Dubrava University Hospital University of Zagreb School of Medicine Zagreb Croatia

Department of Internal Medicine Division of Rheumatology Hacettepe University Ankara Turkey

Department of Pediatric and Adult Rheumatology Faculty Hospital Motol Prague Czech Republic

Department of Rheumatology and Physiotherapy Polyclinic of the Hospitaller Brothers of St John of God Semmelweis University Budapest Hungary

Department of Rheumatology Grigore T Popa University of Medicine and Pharmacy Iași Romania

Faculty of Medicine University of Crete Heraklion Greece

Santa Casa de Belo Horizonte Belo Horizonte Brazil

Zobrazit více v PubMed

Yu C, Jin S, Wang Y, et al. Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol. 2019;38(3):727–738. doi:10.1007/s10067-018-4340-7 PubMed DOI

Batko B, Batko K, Krzanowski M, Żuber Z. Physician adherence to treat-to-target and practice guidelines in rheumatoid arthritis. J Clin Med. 2019;8:9. doi:10.3390/jcm8091416 PubMed DOI PMC

Louder AM, Singh A, Saverno K, et al. Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits. 2016;9(2):84–93. PubMed PMC

Ho MP, Gonzalez JM, Lerner HP, et al. Incorporating patient-preference evidence into regulatory decision making. Surg Endosc. 2015;29(10):2984–2993. doi:10.1007/s00464-014-4044-2 PubMed DOI

FDA guidance: guidance on patient preference information in premarket approval applications, humanitarian device exemption applications, and de novo requests. Available from: http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446680.pdf. Accessed August24, 2016

FDA guidance: patient preference study design – qualitative steps first steps for sponsors initiating a patient preference study. Available from: https://mdic.org/wp-content/uploads/2016/04/Patient-Preference-Study-Design-20171102.pdf. Accessed November2, 2017

Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumatol. 2015;10(5):345–356. doi:10.2217/ijr.15.39 PubMed DOI PMC

Papadimitropoulos M, Mysler E, Garcia E, Lobosco S, Botello B, Leonardi Reyes F. Treatment patterns and satisfaction for rheumatoid arthritis patients in Latin America undergoing advanced therapy. Value Health. 2017;20(9):PA891.

Schäfer M, Albrecht K, Kekow J, et al. Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT. RMD Open. 2020;6:3. doi:10.1136/rmdopen-2020-001290 PubMed DOI PMC

Jackson JL, Chamberlin J, Kroenke K. Predictors of patient satisfaction. Soc Sci Med. 2001;52(4):609–620. doi:10.1016/S0277-9536(00)00164-7 PubMed DOI

Smolen JS, Aletaha D. What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol. 2006;24(6 Suppl 43):S-7–13. PubMed

Van den Bosch F, Ostor AJK, Wassenberg S, et al. Impact of participation in the adalimumab (humira) patient support program on rheumatoid arthritis treatment course: results from the passion study. Rheumatol Ther. 2017;4(1):85–96. doi:10.1007/s40744-017-0061-7 PubMed DOI PMC

Norman CD, Skinner HA. eHealth literacy: essential skills for consumer health in a networked world. J Med Internet Res. 2006;8(2):e9. doi:10.2196/jmir.8.2.e9 PubMed DOI PMC

Durand C, Eldoma M, Marshall DA, Bansback N, Hazlewood GS. Patient preferences for disease-modifying antirheumatic drug treatment in rheumatoid arthritis: a systematic review. J Rheumatol. 2020;47(2):176–187. doi:10.3899/jrheum.181165 PubMed DOI

Radawski C, Genovese MC, Hauber B, et al. Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA. Rheumatol Ther. 2019;6(3):461–471. doi:10.1007/s40744-019-00168-5 PubMed DOI PMC

Alten R, Krüger K, Rellecke J, et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence. 2016;10:2217–2228. doi:10.2147/PPA.S117774 PubMed DOI PMC

Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79. doi:10.1186/1477-7525-1-79 PubMed DOI PMC

Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137–145. doi:10.1002/art.1780230202 PubMed DOI

Ware JE Jr, Sherbourne CD, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483. doi:10.1097/00005650-199206000-00002 PubMed DOI

Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire–general health version in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R177. doi:10.1186/ar3141 PubMed DOI PMC

Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. Aids. 2002;16(2):269–277. doi:10.1097/00002030-200201250-00017 PubMed DOI

De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol. 2016;35(5):1335–1339. doi:10.1007/s10067-016-3182-4 PubMed DOI

Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–2310. doi:10.1185/03007990903126833 PubMed DOI

Richtering SS, Hyun K, Neubeck L, et al. eHealth literacy: predictors in a population with moderate-to-high cardiovascular risk. JMIR Hum Factors. 2017;4(1):e4. doi:10.2196/humanfactors.6217 PubMed DOI PMC

Fayad F, Ziade NR, Merheb G, et al. Patient preferences for rheumatoid arthritis treatments: results from the national cross-sectional LERACS study. Patient Prefer Adherence. 2018;12:1619–1625. doi:10.2147/PPA.S168738 PubMed DOI PMC

Marshall D, Bridges JF, Hauber B, et al. Conjoint analysis applications in health - how are studies being designed and reported?: an update on current practice in the published literature between 2005 and 2008. Patient. 2010;3(4):249–256. doi:10.2165/11539650-000000000-00000 PubMed DOI

Jobanputra P, Maggs F, Deeming A, et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open. 2012;2:6. doi:10.1136/bmjopen-2012-001395 PubMed DOI PMC

Mahlich J, Schaede U, Sruamsiri R. Shared decision-making and patient satisfaction in Japanese rheumatoid arthritis patients: a new “preference fit” framework for treatment assessment. Rheumatol Ther. 2019;6(2):269–283. doi:10.1007/s40744-019-0156-4 PubMed DOI PMC

Hueston WJ, Mainous AG 3rd, Schilling R. Patients with personality disorders: functional status, health care utilization, and satisfaction with care. J Fam Pract. 1996;42(1):54–60. PubMed

Wyshak G, Barsky A. Satisfaction with and effectiveness of medical care in relation to anxiety and depression. Patient and physician ratings compared. Gen Hosp Psychiatry. 1995;17(2):108–114. doi:10.1016/0163-8343(94)00097-W PubMed DOI

Stark JL, Yassine M, Nowell WB, et al. THU0159 Barriers to rheumatoid arthritis treatment optimisation: real-world data from the arthritispower registry. Ann Rheum Dis. 2018;77(Suppl 2):299.

Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1–25. doi:10.1002/acr.22783 PubMed DOI

Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi:10.1136/annrheumdis-2019-216655 PubMed DOI

Yun H, Chen L, Xie F, et al. Do patients with moderate or high disease activity escalate rheumatoid arthritis therapy according to treat-to-target principles? Results from the rheumatology informatics system for effectiveness registry of the American College of Rheumatology. Arthritis Care Res. 2020;72(2):166–175. doi:10.1002/acr.24083 PubMed DOI

Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol. 2014;66(4):775–782. doi:10.1002/art.38323 PubMed DOI PMC

Fleischmann RM, van der Heijde D, Gardiner PV, Szumski A, Marshall L, Bananis E. DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open. 2017;3(1):e000382. doi:10.1136/rmdopen-2016-000382 PubMed DOI PMC

Smolen JS, Gladman D, McNeil HP, et al. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. RMD Open. 2019;5(1):e000585. doi:10.1136/rmdopen-2017-000585 PubMed DOI PMC

Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018;12:1483–1503. doi:10.2147/PPA.S167508 PubMed DOI PMC

Taylor PC, Alten R, Gomez-Reino JJ, et al. Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. RMD Open. 2018;4(1):e000615. doi:10.1136/rmdopen-2017-000615 PubMed DOI PMC

van Vilsteren M, Boot CR, Knol DL, et al. Productivity at work and quality of life in patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2015;16:107. doi:10.1186/s12891-015-0562-x PubMed DOI PMC

Xavier RM, Zerbini CAF, Pollak DF, et al. Burden of rheumatoid arthritis on patients’ work productivity and quality of life. Adv Rheumatol. 2019;59(1):47. doi:10.1186/s42358-019-0090-8 PubMed DOI

Fraenkel L, Bogardus S, Concato J, Felson D. Unwillingness of rheumatoid arthritis patients to risk adverse effects. Rheumatology. 2002;41(3):253–261. doi:10.1093/rheumatology/41.3.253 PubMed DOI

Kim H, Xie B. Health literacy in the eHealth era: A systematic review of the literature. Patient Educ Couns. 2017;100(6):1073–1082. doi:10.1016/j.pec.2017.01.015 PubMed DOI

van der Vaart R, Drossaert CH, de Heus M, Taal E. van de Laar MA. Measuring actual eHealth literacy among patients with rheumatic diseases: a qualitative analysis of problems encountered using Health 1.0 and Health 2.0 applications. J Med Internet Res. 2013;15(2):e27. PubMed PMC